

APPENDIX

PROSTATE GLAND: Systematic +/- Targeted Needle Biopsy

Specimen #:
Patient:
Part:
Initials/Date:

Procedure

Needle Biopsy
Specimen Site
Prostatic structure
Tumor Site

Histologic Type

Adenocarcinoma (acinar, not otherwise specified)
Other (specify) _____

Gleason score/ WHO Grade of worst site/core (list location_____):

Not applicable
Cannot be determined
WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
Who Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10

Global Gleason score/WHO Grade, including systematic and targeted biopsies

WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
WHO Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10
Percent Gleason Patterns 4 and/or 5: _____ %

Cribriform pattern:

Present
Not present
Indeterminate

Intraductal carcinoma:

Present
Not present
Indeterminate
Included in grade assignment

Tumour quantitation & Extent of carcinoma

Number of positive sites:
Total number of sites:
Number of positive cores:
Total number of cores:
Maximum carcinoma extent for Core with the Greatest Amount of Tumour (mm OR % involvement) _____
Maximum carcinoma extent (mm OR % involvement)_____

Method of tumour measurement

Multiple foci counted as continuous core involvement
Multiple foci counted as discontinuous core involvement

Downes MR, et al. Target prostate biopsies: How best to report in synoptic format?

Single continuous focus

Perineural Invasion

+Not identified _____
+Present

Periprostatic Fat Invasion

Not identified _____
Present
Not applicable _____

Seminal Vesicle Invasion*

Not identified _____
Present
Not applicable _____

* SV involvement applicable only if intentional stage biopsy of same performed. The presence of SV/ejaculatory duct epithelium should be noted in report with comment that histology cannot differentiate between the two and correlation with imaging is recommended.

Lympho-Vascular Invasion

Not identified _____
+Present
+Indeterminate _____

Other features

HGPIN _____
Adenosis _____
ASAP _____
Inflammation _____
Other _____

Systematic biopsies (excluding targeted biopsies)

Aggregate Gleason score/WHO Grade
Composite Gleason score/WHO Grade (if applicable) of worst site _____
Not applicable _____
Cannot be determined _____
WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
WHO Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10
Percent Gleason Patterns 4 and/or 5: ____ %

Cribriform pattern:

Present
Not present
Indeterminate

Intraductal carcinoma:

Present
Not present
Indeterminate
Included in grade assignment

Tumour quantitation & Extent of carcinoma

Number of positive sites: _____
Total number of sites:

Downes MR, et al. Target prostate biopsies: How best to report in synoptic format?

Number of Cores Positive _____
Total Number of Cores _____

Maximum carcinoma extent for Core with the Greatest Amount of Tumour (mm OR % involvement) _____
Maximum carcinoma extent (mm OR % involvement)

Method of tumour measurement

Multiple foci counted as continuous core involvement
Multiple foci counted as discontinuous core involvement
Single continuous focus

Targeted lesions (list number and site of positive Targets)*

Not identified
Present

Detected by

DRE
Ultrasound
MRI
Other:
Location:

Composite Gleason score/WHO Grade Target X

Not applicable _____
Cannot be determined _____
WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
WHO Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10
Percent Gleason Patterns 4 and/or 5: _____ %

Cribriform pattern:

Present
Not present
Indeterminate

Intraductal carcinoma:

Present
Not present
Indeterminate
Included in grade assignment

Tumour quantitation & Extent of carcinoma

Number of targeted cores positive _____
Total number of targeted cores _____

Aggregate measurement of carcinoma extent as mm involvement or percentage: _____ %
Maximum carcinoma extent for Core with the Greatest Amount of Tumour (mm OR % involvement) _____

For Negative Target

Benign histology (document same)

* Report each positive Target site separately- necessitates repeating this section per positive Target